LENZ Therapeutics, Inc.

LENZ Healthcare Biotechnology

LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million. In the quarter to June 2026, revenue grew 9.72%, EPS fell 92.5% and free cash flow fell 229.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.27 0.30 −8.40%
Market cap
$112.2M
P/E
0.0×
Fwd P/E
−1.6×
Dividend yield
0.00%
F-score
n/a
Altman Z
11.98
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(59.21%) (49.71%) (33.63%) (28.78%)

+8 more TTM periods

ROA
(55.52%) (46.01%) (31.52%) (27.09%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(58.05%) (44.73%) (29.18%) (30.68%)
Average Days of Receivables
7.51 5.96 0.00 —
Free Cash Flow per Share
(3.65) (2.79) (2.43) (1.62)
Free Cash Flow
(114.42) (87.44) (70.00) (46.16)
Other line items

Show all line items

Columns are period end dates